As we advance our clinical development programs, we also continue to invest in earlier-stage antibody-based therapies to ensure long-term strength of our pipeline. Our current portfolio of preclinical programs includes ASG-5ME and SGN-19A.

asg-5me
We are developing ASG-5ME under a joint development agreement with Agensys, a subsidiary of Astellas Pharma. ASG-5ME combines Agensys' proprietary target and monoclonal antibody with Seattle Genetics' proprietary ADC technology. The companies are currently conducting preclinical studies and manufacturing activities to support planned clinical trials in 2010 for solid tumors.

SGN-19A
SGN-19A is an ADC targeting the CD19 antigen, a pan-B cell marker expressed on many hematologic malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia. Preclinical data demonstrate that SGN-19A effectively binds to target cells, internalizes and induces potent cell-killing activity, including complete tumor regressions in multiple cancer models.